vorinostat has been researched along with Corneal Diseases in 5 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
Corneal Diseases: Diseases of the cornea.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We have previously reported that vorinostat, an FDA-approved, clinically used histone deacetylase (HDAC) inhibitor, attenuates corneal fibrosis in vivo in rabbits by blocking transforming growth factor β (TGFβ)." | 7.81 | Role of 5'TG3'-interacting factors (TGIFs) in Vorinostat (HDAC inhibitor)-mediated Corneal Fibrosis Inhibition. ( Mohan, RR; Sharma, A; Siddiqui, S; Sinha, NR, 2015) |
| "We have previously reported that vorinostat, an FDA-approved, clinically used histone deacetylase (HDAC) inhibitor, attenuates corneal fibrosis in vivo in rabbits by blocking transforming growth factor β (TGFβ)." | 3.81 | Role of 5'TG3'-interacting factors (TGIFs) in Vorinostat (HDAC inhibitor)-mediated Corneal Fibrosis Inhibition. ( Mohan, RR; Sharma, A; Siddiqui, S; Sinha, NR, 2015) |
| "This study was undertaken to evaluate the efficacy of co-treatment with suberoylanilide hydroxamic acid (SAHA) and mitomycin-C (MMC) on corneal fibrosis in an in-vivo model." | 3.80 | The efficacy of co-treatment with suberoylanilide hydroxamic acid and mitomycin C on corneal scarring after therapeutic keratectomy: an animal study. ( Kim, SW; Park, WC; Woo, JE; Yoo, YH, 2014) |
| " Additional in vivo SAHA dosing studies with larger sample size are warranted." | 1.43 | Development of a novel in vivo corneal fibrosis model in the dog. ( Bunyak, F; Giuliano, EA; Gronkiewicz, KM; Hamm, CW; Kuroki, K; Mohan, RR; Sharma, A; Teixeira, LB, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Woo, JE | 1 |
| Park, WC | 1 |
| Yoo, YH | 1 |
| Kim, SW | 1 |
| Sharma, A | 2 |
| Sinha, NR | 1 |
| Siddiqui, S | 1 |
| Mohan, RR | 3 |
| Gronkiewicz, KM | 1 |
| Giuliano, EA | 2 |
| Kuroki, K | 1 |
| Bunyak, F | 1 |
| Teixeira, LB | 1 |
| Hamm, CW | 1 |
| Bosiack, AP | 1 |
| Gupta, R | 1 |
| Li, X | 1 |
| Zhou, Q | 1 |
| Hanus, J | 1 |
| Anderson, C | 1 |
| Zhang, H | 1 |
| Dellinger, M | 1 |
| Brekken, R | 1 |
| Wang, S | 1 |
5 other studies available for vorinostat and Corneal Diseases
| Article | Year |
|---|---|
The efficacy of co-treatment with suberoylanilide hydroxamic acid and mitomycin C on corneal scarring after therapeutic keratectomy: an animal study.
Topics: Animals; Apoptosis; Blotting, Western; Cell Line; Cell Survival; Cicatrix; Corneal Diseases; Cytokin | 2014 |
Role of 5'TG3'-interacting factors (TGIFs) in Vorinostat (HDAC inhibitor)-mediated Corneal Fibrosis Inhibition.
Topics: Cell Transdifferentiation; Cells, Cultured; Cornea; Corneal Diseases; Corneal Injuries; Fibroblasts; | 2015 |
Development of a novel in vivo corneal fibrosis model in the dog.
Topics: Actins; Animals; Biomarkers; Burns, Chemical; Cornea; Corneal Diseases; Disease Models, Animal; Dogs | 2016 |
Efficacy and safety of suberoylanilide hydroxamic acid (Vorinostat) in the treatment of canine corneal fibrosis.
Topics: Animals; Cell Death; Cells, Cultured; Corneal Diseases; Dogs; Fibroblasts; Histone Deacetylase Inhib | 2012 |
Inhibition of multiple pathogenic pathways by histone deacetylase inhibitor SAHA in a corneal alkali-burn injury model.
Topics: Alkalies; Animals; Burns, Chemical; Cornea; Corneal Diseases; Corneal Injuries; Corneal Neovasculari | 2013 |